Definition and epidemiology
Transmissible spongiform encephalopathies (TSEs) are a family of rare, fatal, progressive neurodegenerative diseases caused by abnormal, protease-resistant isoforms of the prion protein. They are called spongiform because of the characteristic vacuolation (sponge-like holes) seen in affected brain tissue on histology.
The prototype and most common human TSE is Creutzfeldt-Jakob disease (CJD), which occurs in several forms:
- Sporadic CJD (sCJD) - about 85-90% of cases; incidence approximately 1-1.5 per million per year worldwide; median age of onset 60-65 years.
- Familial/genetic CJD - about 10-15% of cases; autosomal dominant mutations in the PRNP gene (e.g., E200K).
- Iatrogenic CJD - rare, from contaminated neurosurgical instruments, dura mater grafts, corneal transplants, or human-derived growth hormone.
- Variant CJD (vCJD) - acquired from ingestion of bovine spongiform encephalopathy (BSE, "mad cow disease")-contaminated beef products; affects younger patients (teens to 30s); now very rare after UK food-safety measures.
Other human TSEs include kuru (historically transmitted by ritual cannibalism in Papua New Guinea, now essentially eradicated), Gerstmann-Straussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI), both inherited PRNP mutations. Animal TSEs include BSE in cattle, scrapie in sheep, and chronic wasting disease in deer/elk.
- Prions are misfolded proteins (PrPSc) with no DNA/RNA - they are not killed by standard sterilization or antimicrobials.
- No immune/inflammatory response occurs because PrPSc is a conformational variant of a self-protein, not a foreign antigen.
- Sporadic CJD: rapidly progressive dementia + myoclonus + ataxia in a patient in their 60s, death within 6-12 months.
- EEG shows periodic sharp-wave complexes; MRI DWI shows cortical ribboning; CSF RT-QuIC is the most sensitive/specific test.
- Variant CJD is linked to BSE-contaminated beef, affects younger patients, and presents with psychiatric symptoms before neurologic signs (pulvinar sign on MRI).
- Fatal familial insomnia presents with intractable insomnia and autonomic dysfunction from a PRNP mutation.
- Definitive diagnosis requires brain biopsy/autopsy showing spongiform change, gliosis, and PrPSc immunostaining.
- No disease-modifying treatment exists; management is purely supportive and palliative.
Etiology and risk factors
All TSEs share a common pathogenic agent: the prion (proteinaceous infectious particle), a misfolded isoform of the normal cellular prion protein (PrPC), encoded by the PRNP gene on chromosome 20.
Mechanisms of acquisition
- Sporadic: spontaneous conformational change of PrPC to PrPSc, cause unknown, possibly stochastic misfolding or somatic mutation.
- Genetic: inherited point mutations or insertions in PRNP that favor misfolding (autosomal dominant); examples include E200K (familial CJD), D178N (FFI), and P102L (GSS).
- Acquired/iatrogenic: exposure to prion-contaminated tissue - dura mater or corneal grafts, contaminated neurosurgical/EEG electrodes, cadaveric human growth hormone, or (for vCJD) ingestion of BSE-infected beef, and rare cases from blood transfusion.
Risk factors
- Older age (sporadic CJD)
- Family history of early-onset dementia (genetic forms)
- History of neurosurgery, corneal transplant, or receipt of cadaveric pituitary hormone before screening era
- Methionine homozygosity at codon 129 of PRNP increases susceptibility to sporadic and variant CJD
- Dietary exposure to BSE-contaminated products (vCJD, historical UK risk)
Pathophysiology
The central event is the conversion of normal, protease-sensitive PrPC (rich in alpha-helices) into the abnormal, protease-resistant PrPSc isoform (rich in beta-pleated sheets). PrPSc acts as a template, catalyzing further misfolding of PrPC in a self-propagating, chain-reaction manner - this is the basis of prion "infectivity" without any genetic material.
Accumulated PrPSc aggregates are resistant to normal proteolytic degradation and accumulate within neurons, causing:
- Neuronal vacuolation producing the characteristic spongiform change on histology
- Neuronal loss and gliosis (astrocytic proliferation)
- Amyloid plaque formation in some subtypes (e.g., kuru plaques in vCJD)
Critically, there is no inflammatory infiltrate and no detectable immune response, because the host does not recognize the misfolded protein as foreign (it is simply a conformational variant of a self-protein). This explains the lack of fever, CSF pleocytosis, or response to anti-inflammatory or antimicrobial therapy. Prions are also remarkably resistant to standard sterilization (heat, formaldehyde, routine autoclaving), requiring specialized protocols for decontamination of surgical instruments.
Clinical features
The hallmark of human prion disease is rapidly progressive dementia evolving over weeks to months (far faster than Alzheimer disease).
Classic features of sporadic CJD
- Rapidly progressive cognitive decline/dementia
- Myoclonus (often startle-induced)
- Cerebellar signs (ataxia, gait disturbance)
- Visual disturbances or cortical blindness
- Extrapyramidal and pyramidal signs
- Akinetic mutism in late stages
- Death typically within 6-12 months of symptom onset
Variant CJD distinguishing features
- Younger patients (teens-30s)
- Prominent early psychiatric symptoms (depression, anxiety, withdrawal) before neurologic signs
- Painful sensory symptoms (dysesthesias)
- Longer disease course (median ~14 months) than sporadic CJD
Fatal familial insomnia
- Progressive, intractable insomnia
- Autonomic dysfunction (hyperhidrosis, tachycardia, hypertension)
- Dysautonomia with eventual dementia and ataxia
Kuru / GSS
- Kuru: progressive cerebellar ataxia followed by dementia
- GSS: slowly progressive cerebellar ataxia with later dementia, longer course (years)
Diagnosis
Diagnosis is largely clinical, supported by characteristic ancillary findings, since brain biopsy (the definitive test) is rarely performed due to risk and limited treatment implications. Definitive diagnosis requires neuropathologic examination (brain biopsy or autopsy) showing spongiform change, neuronal loss, gliosis, and PrPSc detection by immunohistochemistry or western blot.
Key supportive investigations
| Test | Finding |
|---|---|
| EEG | Periodic sharp-wave complexes (classic for sporadic CJD, less common in vCJD) |
| MRI brain (DWI/FLAIR) | Cortical ribboning and basal ganglia/thalamic hyperintensity ("pulvinar sign" in vCJD) |
| CSF | Elevated 14-3-3 protein, elevated tau protein; RT-QuIC (real-time quaking-induced conversion) assay highly sensitive and specific for PrPSc |
| Tonsil biopsy | Useful in suspected vCJD (lymphoid accumulation of PrPSc), not in sporadic CJD |
| Genetic testing | PRNP gene sequencing for suspected familial CJD, GSS, FFI |
Diagnostic approach
- A rapidly progressive dementia with myoclonus and ataxia should prompt MRI (DWI/FLAIR), EEG, and CSF studies (14-3-3, tau, RT-QuIC).
- RT-QuIC on CSF or nasal brushing is now the most sensitive and specific non-invasive test and has largely replaced reliance on 14-3-3 alone.
- Standard CSF cell count and protein are typically normal (no pleocytosis), which helps exclude infectious/inflammatory causes.
Differential diagnosis
Because CJD presents with rapidly progressive dementia, the differential is broad and includes treatable mimics that must be excluded:
- Autoimmune/paraneoplastic encephalitis (e.g., anti-NMDA receptor, anti-LGI1) - often treatable, so must be ruled out
- Hashimoto encephalopathy (steroid-responsive encephalopathy)
- Viral encephalitis (HSV encephalitis - CSF pleocytosis present, unlike CJD)
- Rapidly progressive Alzheimer disease or Lewy body dementia - typically slower course
- Vascular dementia / CNS vasculitis
- Toxic-metabolic encephalopathy (hepatic, uremic, drug-induced)
- Wernicke encephalopathy / vitamin deficiencies (B12, thiamine)
- CNS lymphoma or other neoplasms
- Neurosyphilis
Management
There is no curative or disease-modifying treatment for any human prion disease; management is entirely supportive and palliative, consistent with international guideline consensus (WHO, CDC, European expert groups).
Supportive measures
- Symptomatic control of myoclonus (e.g., clonazepam or valproate as adjuncts, not disease-modifying)
- Management of agitation, psychiatric symptoms, and behavioral disturbance
- Nutritional support (often requiring feeding tube in late disease)
- Early palliative care and advance care planning given uniformly fatal, rapid course
- Caregiver and family counseling, given rapid functional decline
Infection control considerations
- Prions resist standard sterilization; instruments used in high-risk neurosurgical/ophthalmologic procedures on suspected cases require specialized decontamination protocols (extended autoclaving, specific chemical treatments) or disposal
- Standard precautions suffice for routine patient care; CJD is not spread by casual contact
- Public health reporting is required in most jurisdictions given the rare but serious iatrogenic and public health implications (e.g., surveillance for vCJD linked to BSE)
Investigational therapies
- Agents such as flupirtine, quinacrine, pentosan polysulfate, and anti-PrP monoclonal antibodies have been studied but none have shown proven survival or functional benefit in clinical trials to date
Complications and prognosis
Prognosis is uniformly poor. Sporadic CJD typically progresses to death within 6 months to 1 year of symptom onset. Variant CJD has a somewhat longer course (median ~14 months). GSS and familial forms may progress over several years. Kuru, now essentially eradicated, followed a course of months to a few years.
Complications
- Progressive immobility and bed-bound state
- Aspiration pneumonia (common terminal event)
- Pressure ulcers and venous thromboembolism from immobility
- Akinetic mutism and total functional dependence in late stages
- Death, usually from secondary infection (aspiration pneumonia, sepsis) or central respiratory/autonomic failure
There is no reported case of spontaneous recovery; survival beyond 2 years is exceptional for sporadic CJD.
"SPONGE" for spongiform encephalopathy features: Spongiform vacuolation, Protease-resistant PrPSc, Only self-protein (no immune response), No DNA/RNA agent, Gliosis without inflammation, EEG periodic sharp waves.
Practice questions
1. A 64-year-old woman presents with a 3-month history of rapidly progressive memory loss and confusion. Her family reports sudden jerking movements of her limbs that worsen with loud noises. Neurologic exam shows myoclonus and ataxia. MRI shows cortical ribboning on diffusion-weighted imaging, and EEG shows periodic sharp-wave complexes. Which of the following best explains the underlying pathophysiology of her condition?
2. A 24-year-old man from the United Kingdom presents with 6 months of depression, anxiety, and social withdrawal, followed by development of painful dysesthesias and ataxia. MRI shows increased signal in the posterior thalamus bilaterally. Which of the following is the most likely diagnosis?
3. A hospital is preparing to reuse neurosurgical instruments after a procedure on a patient later diagnosed with Creutzfeldt-Jakob disease. Which of the following statements about decontamination is correct?
Frequently asked questions
What causes transmissible spongiform encephalopathy?
TSE is caused by misfolded prion proteins (PrPSc) that convert normal cellular prion protein (PrPC) into the abnormal form, triggering a self-propagating chain reaction. This can occur spontaneously (sporadic CJD), through inherited PRNP mutations (familial CJD, GSS, fatal familial insomnia), or through exposure to prion-contaminated tissue, surgical instruments, or BSE-infected beef (iatrogenic and variant CJD).
What are the first symptoms of prion disease?
In sporadic CJD, early symptoms are usually subtle cognitive changes, memory problems, and personality changes, quickly followed by myoclonus and gait or balance problems. Variant CJD often begins instead with psychiatric symptoms like depression, anxiety, or social withdrawal, with neurologic signs appearing weeks to months later. Progression is faster than typical dementias, often becoming obvious within weeks.
How is prion disease diagnosed?
Diagnosis combines clinical features (rapidly progressive dementia with myoclonus) with supportive tests: EEG (periodic sharp-wave complexes), brain MRI (cortical ribboning, basal ganglia changes), and CSF studies including the RT-QuIC assay, which is now the most sensitive and specific non-invasive test for prion protein. Definitive confirmation requires brain biopsy or autopsy, but this is rarely needed clinically.
Is prion disease curable?
No, prion disease is not curable and is universally fatal. There is currently no treatment that stops or reverses disease progression; care is limited to supportive and palliative measures such as symptom control, nutritional support, and family counseling. Most patients with sporadic CJD die within 6 to 12 months of symptom onset.
Sporadic CJD vs variant CJD - what is the difference?
Sporadic CJD typically affects older adults (60s), arises spontaneously, and progresses rapidly over months with myoclonus and dementia as early features. Variant CJD affects younger people, is acquired from BSE-contaminated beef, starts with psychiatric symptoms rather than cognitive decline, shows a pulvinar sign on MRI, and has a somewhat longer disease course of around 14 months.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: A81
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.